×

Valeant misses on top and bottom line

6:08 AM ET Tue, 9 Aug 2016

CNBC's Meg Tirrell breaks down Valeant Pharmaceuticals' quarterly numbers which reported EPS of $1.40 Adj. on revenues of $2.42 billion.